Protagonist Therapeutics Inc (PTGX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.55B
Last updated: Nov 17, 2026 at 4:33 PM ET
Protagonist Therapeutics Inc (PTGX) Statistics
Protagonist Therapeutics (PTGX) has a market cap of $8.55B and an enterprise value of $8.05B. Revenue grew 163.69% over the last 12 months from the 12 months before. It kept 62.04% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 5.83% below the market cap, as cash exceeds debt.
| Market Cap | $8.55B |
|---|---|
| Enterprise Value | $8.05B |
| Latest price (Nov 17, 2026) | $124.67 |
Key Dates
The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 23, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 15.0x and 7.6x.
| P/E Ratio | 26.4x |
|---|---|
| Forward P/E | 24.8x |
| P/S Ratio | 15.0x |
| Forward P/S | 15.1x |
| P/B Ratio | 7.6x |
| P/FCF Ratio | 75.8x |
| P/OCF Ratio | 77.8x |
Enterprise Valuation
Counting debt and cash, the company is valued at 24.3x EBITDA and 71.2x free cash flow.
| EV / Earnings | 23.5x |
|---|---|
| EV / Sales | 14.6x |
| EV / EBITDA | 24.3x |
| EV / FCF | 71.2x |
Price Statistics
The stock is up 47.35% over 52 weeks and trades 10.61% below its 50-day average.
| Beta (1Y) | 0.94 |
|---|---|
| 52-Week Change | +47.35% |
| 1-Month Change | -7.27% |
| 3-Month Change | -19.54% |
| 6-Month Change | +26.74% |
| 5-Year Change | +364.86% |
| 10-Year Change | +670.48% |
| Total Return (1Y) | +47.35% |
| Total Return (3Y CAGR) | +94.98% |
| Total Return (5Y CAGR) | +27.93% |
| Return vs SPY (1Y) | +36.17% |
| Max Drawdown (1Y) | -21.40% |
| Max Drawdown (3Y) | -31.58% |
| Sharpe Ratio (1Y) | 0.98 |
| Correlation with SPY (1Y) | 0.32 |
| 50-Day Average | $139.46 |
| 200-Day Average | $119.71 |
| 52-Week Range | $77.00 to $160.81 |
| RSI (14 Days) | 32.5 |
| Average Volume (20 Days) | 586.97K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 19.85x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 19.85x |
|---|---|
| Quick Ratio | 19.85x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is 31.55% over the last 12 months, against a 5-year average of -20.96%.
| Return on Equity (ROE) | 31.55% |
|---|---|
| Return on Assets (ROA) | 29.85% |
| ROE (5Y Average) | -20.96% |
| ROA (5Y Average) | -18.42% |
| ROIC (5Y Average) | -25.72% |
| Asset Turnover | 0.60x |
Taxes
Income tax took 2.28% of pretax income over the last 12 months.
| Income Tax (TTM) | $7.99M |
|---|---|
| Effective Tax Rate | 2.28% |
Scores
PTGX has an Altman Z-Score of 82.93, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 82.93 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $551.69M over the last 12 months.
| Revenue | $551.69M |
|---|---|
| Revenue Growth (YoY) | +163.69% |
| Gross Profit | $550.59M |
| Operating Income | $323.10M |
| Pretax Income | $350.25M |
| Net Income | $342.26M |
| Reported EPS (TTM) | $4.72 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 93.91% of the $1.15B in total assets.
| Cash and Equivalents | $498.30M |
|---|---|
| Total Debt | $0 |
| Net Cash | $498.30M |
| Net Cash Per Share | $7.51 |
| Working Capital | $1.05B |
| Shareholder Equity | $1.08B |
| Book Value Per Share | $16.35 |
| Total Assets | $1.15B |
| Total Liabilities | $61.64M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $764.00K of capital spending, operating cash flow left $109.15M of free cash flow.
| Operating Cash Flow | $109.91M |
|---|---|
| Capital Expenditures | $764.00K |
| Free Cash Flow | $109.15M |
| FCF Per Share | $1.69 |
| Depreciation and Amortization | $6.08M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 58.56%.
| Gross Margin | 99.80% |
|---|---|
| Operating Margin | 58.56% |
| Pretax Margin | 63.49% |
| Net Margin | 62.04% |
| FCF Margin | 19.78% |
Growth
Revenue grew 20.07% a year over 3 years.
| Revenue Growth (3Y CAGR) | +20.07% |
|---|---|
| Revenue Growth (5Y CAGR) | +9.96% |
| Book Value Per Share Growth (2Y CAGR) | +33.22% |
| Tangible Book Per Share Growth (2Y CAGR) | +33.22% |
Dividends and Yields
PTGX does not pay a dividend. Its free cash flow yield is 1.32%.
| Earnings Yield | 3.79% |
|---|---|
| FCF Yield | 1.32% |
| Buyback Yield | -0.60% |
| Shareholder Yield | -0.60% |
Peer Position
Against 3 similar companies, PTGX has the lowest P/E.
P/E RatioPeer median 64.7x
P/S RatioPeer median 11.1x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +20.11%
| P/E Ratio | 26.4x vs 64.7x median |
|---|---|
| P/S Ratio | 15.0x vs 11.1x median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +163.69% vs +20.11% median |
Analyst Forecast
Consensus estimates put revenue growth at 126.36% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +126.36% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PTGX
What is PTGX's market cap?
Protagonist Therapeutics has a market cap of $8.55B. Its enterprise value, which adds debt and subtracts cash, is $8.05B.
What is PTGX's P/E ratio?
Protagonist Therapeutics has a trailing P/E ratio of 26.4x and a forward P/E of 24.8x.
How many shares of PTGX are outstanding?
Protagonist Therapeutics has 66.36M shares outstanding. The count is up 4.06% from a year earlier.
Does PTGX pay a dividend?
No. Protagonist Therapeutics does not pay a dividend.
How much debt does PTGX have?
Protagonist Therapeutics has $0 of total debt and $498.30M of cash and equivalents, a net cash position of $498.30M.
PTGX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors